Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is the global pioneer in RNA interference therapeutics, translating the Nobel Prize-winning science of RNAi into a whole new class of innovative medicines. The enterprise develops and commercializes targeted gene-silencing therapies that turn off disease-causing proteins before they are produced, including treatments for amyloidosis and acute hepatic porphyria. Through proprietary GalNAc delivery platforms and RNA chemistry, Alnylam Pharmaceuticals develops targeted genetic therapies for rare and prevalent disorders.